Missing Script

Get updates

Evidence Explorer / MS-N208 / Supportive physical care / Appraised November 1, 2026

A small 2026 randomized active-controlled trial tested a cream containing an AIMP1-derived peptide after mastectomy, reconstruction and adjuvant radiotherapy. Twenty-three of 30 randomized participants completed follow-up. Some later symptom and scar measures favored NeoPep-S, but the small sample, attrition and multiple outcomes make the evidence preliminary.

Evidence at a glance

  • Population: 30 randomized after mastectomy and reconstruction; 23 completed (15 NeoPep-S, 8 control).
  • Comparator: conventional moisturizing barrier-repair cream.
  • Primary-type skin measure: transepidermal water-loss recovery was similar at one month (P=.877).
  • Other findings: three-month scar score, pain and pruritus measures favored NeoPep-S in reported analyses.
  • Evidence label: preliminary, inconclusive small-trial evidence.

What was studied

The report was published online October 24, 2026. It assessed transepidermal water loss, modified Vancouver Scar Scale, pruritus and BREAST-Q outcomes at baseline, one month and three months.

At three months the investigators reported a favorable scar-score difference (P=.019); pain comparisons favored NeoPep-S at both follow-ups (P=.023 and .002). Complete pruritus resolution was reported in 100% vs 50%. With only 23 completers and several outcomes, these estimates are unstable and need replication.

What this evidence cannot establish

The abstract does not provide absolute mean changes, confidence intervals, a clearly identified prespecified primary endpoint, adverse-event counts, adherence, funding or conflicts. Those fields remain not reported or not verified.

This study addresses recovery and symptoms after radiotherapy in a reconstruction population. It does not show prevention of high-grade acute dermatitis, protection from implant loss, improved cancer treatment delivery or cancer control.

Practical safety context

A new topical product can cause irritation or allergy and may interact with dressings or local wound care. Use around reconstructed tissue should be coordinated with radiation oncology and plastic surgery.

New drainage, wound separation, fever, implant exposure, spreading redness or escalating pain needs prompt clinical assessment—not another topical layer.

Questions for the care team

  • Which outcome matters most in my case: acute dermatitis, wound healing, scar symptoms or comfort?
  • Is the product compatible with my reconstruction and current dressings?
  • What evidence would make the team stop or continue it?

Sources

Source note: Only the PubMed abstract and bibliographic metadata were accessible for appraisal. Unsupported dosing and formulation details were intentionally omitted. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.